MustGrow Biologics (TSE:MGRO)
:MGRO
Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.49
C$0.01(0.67%)
At close: 4:00 PM EST
C$0.49
C$0.01(0.67%)
Day’s Range― - ―
52-Week RangeC$0.49 - C$1.15
Previous CloseN/A
Volume4.97K
Average Volume (3M)27.52K
Market Cap
C$33.55M
Enterprise ValueC$32.62M
Total Cash (Recent Filing)C$918.77K
Total Debt (Recent Filing)C$584.13K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,854,360
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)27.35
Price to Sales (P/S)149.08
P/FCF Ratio-16.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth / Commercialization ProgressA nearly 10x TTM revenue increase demonstrates tangible commercialization and customer traction for the company's biologic products. Over a 2-6 month horizon this supports scaling, OEM/partner negotiations, and evidence of market fit that can underwrite further commercial investment and distribution expansion.
Modest LeverageLow debt relative to equity preserves financial flexibility to fund R&D, regulatory work, and commercialization without heavy interest burden. This structural cushion reduces bankruptcy risk and gives management options for incremental capital raises or strategic partnerships over the medium term.
Business Model Centered On Biologics And PartnershipsA product-led biologics strategy plus partner distribution creates a scalable commercial model and structural advantages: IP-backed inputs, regulatory barriers to entry, and partner channels that can accelerate market reach while limiting fixed sales costs as the commercial base grows over multiple seasons.
Bears Say
Sustained Negative Cash Flow / Cash BurnPersistent negative operating and free cash flow indicate the business is consuming capital to operate and expand. Over months this necessitates external funding or equity dilution, which can constrain strategic choices, slow commercialization cadence, and elevate execution risk if revenue growth slows.
Very Weak Profitability And MarginsLow gross margin and extreme operating losses show the current unit economics are poor. Without material margin improvement or scale-driven cost leverage, the company faces a long runway to profitability, increasing dependency on continued top-line expansion and external capital to sustain operations.
Revenue Volatility And Unstable BaseHigh year-over-year growth off a very small prior base implies revenue is lumpy and may be project or season dependent. This instability complicates forecasting, weakens ability to cover fixed costs reliably, and raises execution risk for scaling manufacturing, regulatory timelines, and partner commitments.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.49 and its highest was C$1.15 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$33.55M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is May 21, 2026 which is in 19 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 58,854,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---